Rohin Iyer Highlights Rising Approval Rates and Cold Chain Challenges in Cell and Gene Therapy at Advanced Therapies Week 2025

At Advanced Therapies Week 2025, Rohin Iyer, Senior Director of Global Cell and Gene Therapy (CGT) Operations at Marken, discussed key developments shaping the advanced therapies sector. In an interview, Iyer highlighted several notable trends, including rising approval rates for both allogeneic and autologous therapies, significant growth in the cell and gene therapy industry, and a shift toward earlier adoption of these treatments due to their curative potential. His remarks provided insight into the evolving landscape of advanced therapies as they gain traction in addressing complex medical conditions.

Iyer also addressed challenges and opportunities within the CGT industry as it moves forward. He emphasized issues related to scalability and cold chain logistics—critical components for ensuring the safe transport and delivery of temperature-sensitive therapies. Additionally, he outlined how Marken, a division of UPS Healthcare Precision Logistics, is contributing to advancements in this field by developing innovative solutions tailored to meet its dynamic needs. The discussion underscored Marken’s role in navigating logistical complexities while supporting the continued expansion of advanced therapeutic options worldwide.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 2, 2025

Related posts:

Pharmaceutical Guide Helps Professionals Identify Key Similar Medicines to Inform Pricing Strategies. Biosimilars Now Over 20% of European Generic Market, Driving Industry Transformation Study Finds Mortality Prediction Tools Ineffective for Elderly Patients with Advanced Chronic Kidney Disease Trump Administration Proposal Could Reclassify NIH Directors as Political Appointees

Author

Mark Chiang